AGA Family of Websites: Gastro.org
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
April 16, 2019

Three new resources from AGA on biosimilars

New biosimilars education is available for both your practice and your patients.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Biosimilars are emerging as an increasingly common treatment for inflammatory bowel disease (IBD), as the initial biologic therapies introduced to treat IBD nearly 20 years ago are nearing the end of their patents. Here are three new educational resources for your practice and patients: 
    • 1. Text: Patient education pages on biosimilars

Share this new education resource by directing your patients to the website links above, printing hard copies, posting them to your practice website or adding to your electronic health record (EHR) system. Instructions for Athena, Cerner, Epic and gMed:

    • 2. Videos: What are biologic and biosimilar drugs?
    • These short and visually compelling videos will help patients understand the difference between biologics and biosimilars. Embed the YouTube link to your website and share on social media.
    • 3. Clinical practice update (CPU): Switching between biologics and biosimilars in inflammatory bowel disease

 

 
    • Published in Clinical Gastroenterology and Hepatology this month, this AGA clinical practice update provides an overview of biosimilars, their manufacturing process, the FDA approval process, and the data available describing their safety and efficacy.
Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.